Home > Publications Database > Characterization of Peripapillary Hyperreflective Ovoid Mass-like Structures in a Broad Spectrum of Neurologic Disorders. > print

001     278074
005     20250504001228.0
024 7 _ |a 10.1016/j.ophtha.2024.12.013
|2 doi
024 7 _ |a pmid:39675637
|2 pmid
024 7 _ |a 0161-6420
|2 ISSN
024 7 _ |a 1549-4713
|2 ISSN
024 7 _ |a altmetric:172021708
|2 altmetric
037 _ _ |a DZNE-2025-00565
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Gernert, Jonathan A
|b 0
245 _ _ |a Characterization of Peripapillary Hyperreflective Ovoid Mass-like Structures in a Broad Spectrum of Neurologic Disorders.
260 _ _ |a Amsterdam [u.a.]
|c 2025
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1746002870_22983
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Peripapillary hyperreflective ovoid mass-like structures (PHOMSs) have been identified in ophthalmic and neurologic diseases. Because PHOMSs were found more frequently in these cohorts compared with healthy control participants, it is assumed that the presence of PHOMSs reflects a secondary disease marker of unknown significance. The extent to which disease-specific differences are reflected in PHOMSs has not yet been investigated sufficiently.Monocentric, retrospective study.We analyzed a large cohort of people with a broad spectrum of neurologic disorders, including neuroimmunologic diseases (NIDs; n = 237), epilepsy (n = 153), movement disorders (MDs; n = 44), intracranial hypertension (IH; n = 13), and inborn errors of metabolism (n = 90).We analyzed the prevalence, location, volume, and intensity of PHOMSs. Peripapillary hyperreflective ovoid mass-like structure volumes were correlated with demographic and other OCT parameters.Prevalence, location, volume, and intensity of PHOMSs.We identified PHOMSs in 7% of the analyzed eyes. Peripapillary hyperreflective ovoid mass-like structures were detected in all cohorts, and their location was predominantly nasal. The median volume of all PHOMSs was 0.06 mm3. However, the median PHOMS volume was increased in those with IH compared with those with NID (P = 0.009), epilepsy (P = 0.038), or MDs (P = 0.027). The PHOMS volume correlated positively with the opening of the Bruch membrane and correlated negatively with the age of the cohort after the exclusion of patients with IH. Overall, PHOMS intensity was comparable with that of the optic nerve.Because larger PHOMS volumes were found in individuals with IH, a mechanistic link to increased intracranial pressure can be assumed. It remains unclear whether this explanation also applies to individuals with other neurologic disorders with PHOMSs. Because PHOMSs have a relevant influence on OCT parameters, their presence also should be considered in nonophthalmic scientific studies in the future.Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Neurologic disorders
|2 Other
650 _ 7 |a OCT
|2 Other
650 _ 7 |a PHOMS
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Retrospective Studies
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Tomography, Optical Coherence: methods
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Optic Disk: pathology
|2 MeSH
650 _ 2 |a Nervous System Diseases: diagnosis
|2 MeSH
650 _ 2 |a Nervous System Diseases: complications
|2 MeSH
650 _ 2 |a Young Adult
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Adolescent
|2 MeSH
650 _ 2 |a Child
|2 MeSH
700 1 _ |a Christmann, Tara
|b 1
700 1 _ |a Kaufmann, Elisabeth
|b 2
700 1 _ |a Delazer, Luisa
|b 3
700 1 _ |a Kirsch, Isabel
|0 P:(DE-2719)9002725
|b 4
|u dzne
700 1 _ |a Levin, Johannes
|0 P:(DE-2719)2811659
|b 5
|u dzne
700 1 _ |a Schönecker, Sonja
|b 6
700 1 _ |a Fietzek, Urban
|0 P:(DE-2719)9001214
|b 7
|u dzne
700 1 _ |a Eulenburg, Peter Zu
|b 8
700 1 _ |a Velten, Theresa
|b 9
700 1 _ |a Gripshi, Marina
|b 10
700 1 _ |a Parhofer, Klaus G
|b 11
700 1 _ |a Maier, Esther M
|b 12
700 1 _ |a Kümpfel, Tania
|b 13
700 1 _ |a Lotz-Havla, Amelie S
|b 14
700 1 _ |a Havla, Joachim
|b 15
773 _ _ |a 10.1016/j.ophtha.2024.12.013
|g Vol. 132, no. 5, p. 590 - 597
|0 PERI:(DE-600)2015287-5
|n 5
|p 590 - 597
|t Ophthalmology
|v 132
|y 2025
|x 0161-6420
856 4 _ |u https://pub.dzne.de/record/278074/files/DZNE-2025-00565%20SUP.zip
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/278074/files/DZNE-2025-00565.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/278074/files/DZNE-2025-00565.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:278074
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 4
|6 P:(DE-2719)9002725
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2811659
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 7
|6 P:(DE-2719)9001214
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-12
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b OPHTHALMOLOGY : 2022
|d 2024-12-12
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b OPHTHALMOLOGY : 2022
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-12
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-12
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-12
920 1 _ |0 I:(DE-2719)1111016
|k AG Levin
|l Clinical Neurodegeneration
|x 0
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1111016
980 _ _ |a I:(DE-2719)1111015
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21